- Home
- NIM vs COYA Comparison
NIM vs COYA Comparison
Compare NIM & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIM
- COYA
- Stock Information
- Founded
- NIM 1992
- COYA 2020
- Country
- NIM United States
- COYA United States
- Employees
- NIM N/A
- COYA N/A
- Industry
- NIM Trusts Except Educational Religious and Charitable
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- NIM Finance
- COYA Health Care
- Exchange
- NIM Nasdaq
- COYA Nasdaq
- Market Cap
- NIM 111.9M
- COYA 103.2M
- IPO Year
- NIM N/A
- COYA 2022
- Fundamental
- Price
- NIM $9.13
- COYA $6.05
- Analyst Decision
- NIM
- COYA Strong Buy
- Analyst Count
- NIM 0
- COYA 4
- Target Price
- NIM N/A
- COYA $17.00
- AVG Volume (30 Days)
- NIM 35.4K
- COYA 69.3K
- Earning Date
- NIM 01-01-0001
- COYA 05-16-2025
- Dividend Yield
- NIM 3.46%
- COYA N/A
- EPS Growth
- NIM N/A
- COYA N/A
- EPS
- NIM N/A
- COYA N/A
- Revenue
- NIM N/A
- COYA $3,554,061.00
- Revenue This Year
- NIM N/A
- COYA $94.45
- Revenue Next Year
- NIM N/A
- COYA N/A
- P/E Ratio
- NIM N/A
- COYA N/A
- Revenue Growth
- NIM N/A
- COYA N/A
- 52 Week Low
- NIM $8.28
- COYA $4.65
- 52 Week High
- NIM $9.74
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- NIM 47.98
- COYA 49.30
- Support Level
- NIM $9.08
- COYA $5.77
- Resistance Level
- NIM $9.22
- COYA $6.59
- Average True Range (ATR)
- NIM 0.17
- COYA 0.54
- MACD
- NIM -0.01
- COYA 0.01
- Stochastic Oscillator
- NIM 31.48
- COYA 24.81
About NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital by investing in an investment-grade quality portfolio of municipal obligations with intermediate characteristics.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.